We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the Pulmonary Vascular Reactivity Test in Patients With Pulmonary Arterial Hypertension and a Cardiac Shunt (ReVAch)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02138708
Recruitment Status : Withdrawn (Lack of financing)
First Posted : May 15, 2014
Last Update Posted : March 26, 2021
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to assess the predictive performance of the pulmonary vascular reactivity to acetylcholine, in the presence pulmonary arterial hypertension (estimated 1 year after the closure of the shunt).

Condition or disease Intervention/treatment Phase
Pulmonary Arterial Hypertension With Congenital Cardiac Shunt Other: Pharmacological test of pulmonary endothelial Not Applicable

Detailed Description:

Pulmonary arterial hypertension (PAH) is an important cause of mortality and morbidity in patients with congenital heart disease with a shunt.

These congenital cardiac shunts are responsible for PAH, which evolves towards higher pulmonary vascular resistance if they are not closed early.

Patients with significant pulmonary flow and low pulmonary vascular resistance fully benefit from surgical shunt closure with complete disappearance of pulmonary hypertension after closure. In contrast, patients with low pulmonary flow and high pulmonary vascular resistance will have no benefit because they keep a deleterious pulmonary hypertension after closure of the shunt.

In certain situations, especially late discovery of heart disease, the issue of operability of these patients is crucial because closing the shunt inappropriately worsens the spontaneous prognosis. Currently, in case of doubt on the operability, there are several clinical and hemodynamic criteria used empirically, but their predictive value is uncertain.

It is therefore necessary to stratify patients into operable and inoperable groups to improve their overall outcome after surgery.

In this research project we propose to assess the predictive performance of the pulmonary vascular reactivity to acetylcholine test on the presence of elevated PAH 1 year after the closure of the shunt. This reactivity test will be evaluated on a population of patients for whom the decision of the surgical closure of the shunt has been adjudicated on the basis of explorations and usual tests (and therefore blind to the knowledge of the result of the reactivity test). The test in this study is designed with repeated injections and increasing doses with a continuous flow of acetylcholine in the left lower lobe of the pulmonary artery. The last injection consisted with adenosine with inhaled O2/NO (potentiating effect) for maximum vasodilatation. The parameter of interest is the Doppler flow velocity in the pulmonary artery endothelium-dependent vasodilation by acetylcholine relative to the speed at maximum vasodilatation (adenosine + in nitric oxide (NO) inhalation)

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Pharmacological Test of Pulmonary Endothelium-dependent Vascular Reactivity to Acetylcholine in Pulmonary Arterial Hypertension With Congenital Cardiac Shunt Child and Adult
Estimated Study Start Date : January 2016
Actual Primary Completion Date : March 2016
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Shunt closed
patients with heart disease and shunt who, following hemodynamic exploration, will be selected for closure of their shunt
 Other: Pharmacological test of pulmonary endothelial
Other Names:
  • Before any shunt closure operation, the patients will have a the endothelium-dependant reactivity test.
  • This includes for the same patient :
  • - Implementation of Doppler probe in the lower left lobe guided in one probe 5 catheter guide right coronary 5 Fr
  • - then control infusion G5%
  • - then, 3 successive acetylcholine infusions to locally obtain successive concentrations of 10-10, 10-8, 10-6 mol /L
  • - and infusion of adenosine 50μg/Kg/min with NO inhald/FiO2 100%


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Predictive performance of the reactivity test to the occurence of pulmonary arterial hypertension one year after the closure of the shunt. [ Time Frame: 1 year +/- 2 months ]

    Evaluated in patient with "shunt closed" by :

    • the area under the ROC curve.
    • the parameter of interest is the Doppler flow velocity in m / s in endothelium-dependent vasodilation by acetylcholine relative to the speed in m / s at maximum vasodilatation (adenosine + in nitric oxide (NO) inhalation)
    • presence or absence of PAH one year after closure of the shunt will be evaluated by a conventional cardiac catheterization


Secondary Outcome Measures :
  1. occurrence of pulmonary hypertension. [ Time Frame: 1 year +/- 2 months ]
  2. Nature and frequency of adverse events [ Time Frame: 1 year +/- 2 months ]
  3. Characteristic of the distribution of test of reactivity in the population "shunt unclosed" [ Time Frame: 1 year +/- 2 months ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient child or adult, (regardless of age and weight) , which presents with heart disease with a shunt,
  • Patient who requires, during current care, a hemodynamic exploration by catheterization to assess pulmonary vascular resistance (due to doubt on the operability of the patient on the usual clinical and echo cardiographic data) .
  • Informed consent signed by the patient or at least one holder of parental authority, and the investigator
  • Patient affiliated or benefiting from a social security scheme

Exclusion Criteria:

  • Patient with a specific treatment for PAH (the prostacyclin derivatives, antagonists of endothelium receptors and inhibitors of phosphodiesterase 5).
  • Patient participating in another research with exclusion period
  • Known allergy to acetylcholine or adenosine
  • Contraindication to the use of KRENOSIN (adenosine)
  • atrioventricular block second or third degree, with the exception of patients with cardiac pacemaker.
  • dysfunction sinoatrial (the headset disease) except patients with a pacemaker
  • chronic obstructive pulmonary disease with bronchospasm (eg bronchial asthma)
  • long QT Syndrome
  • severe arterial hypotension
  • known adenosine hypersensitivity
  • Pregnant or patient of childbearing potential not using an effective contraception
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

No Contacts or Locations Provided
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT02138708    
Other Study ID Numbers: P120910
First Posted: May 15, 2014    Key Record Dates
Last Update Posted: March 26, 2021
Last Verified: March 2021
Keywords provided by Assistance Publique - Hôpitaux de Paris:
Pulmonary arterial hypertension,
congenital heart disease,
heart shunt,
acetylcholine
Pharmacological test of pulmonary vascular reactivity (acetylcholine) in
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Arterial Hypertension
Familial Primary Pulmonary Hypertension
Hypertension
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases
Adenosine
Acetylcholine
Analgesics
Sensory System Agents
 Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Vasodilator Agents
Purinergic P1 Receptor Agonists
Purinergic Agonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Cholinergic Agonists
Cholinergic Agents